• LAST PRICE
    4.3700
  • TODAY'S CHANGE (%)
    Trending Down-0.0600 (-1.3544%)
  • Bid / Lots
    4.2600/ 3
  • Ask / Lots
    4.4400/ 3
  • Open / Previous Close
    4.4400 / 4.4300
  • Day Range
    Low 4.3501
    High 4.4400
  • 52 Week Range
    Low 2.1200
    High 4.9500
  • Volume
    26,869
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 4.43
TimeVolumeDMAC
09:32 ET2254.44
09:35 ET1004.37
10:15 ET22814.365
10:27 ET14004.37
10:47 ET1004.375
10:56 ET1004.375
10:58 ET1004.4
11:09 ET1004.39
11:21 ET1004.37
11:25 ET1004.375
11:59 ET1064.39
12:08 ET10144.375
12:33 ET1464.385
12:35 ET3004.4
01:15 ET22004.42
01:33 ET6004.41
01:40 ET1004.42
02:09 ET4904.43
02:21 ET1004.43
02:36 ET4654.43
02:52 ET1004.43
02:54 ET4004.43
02:59 ET1004.427
03:01 ET1004.425
03:08 ET8554.43
03:17 ET12514.425
03:30 ET4004.4203
03:32 ET2004.425
03:33 ET1004.43
03:39 ET12404.43
03:42 ET2004.425
03:46 ET1004.425
03:48 ET1004.43
03:50 ET1004.42
03:51 ET1004.42
03:53 ET2004.425
03:55 ET1004.42
04:00 ET30204.37
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesDMAC
DiaMedica Therapeutics Inc
189.4M
-8.3x
---
United StatesTNYA
Tenaya Therapeutics Inc
190.1M
-1.4x
---
United StatesCABA
Cabaletta Bio Inc
195.4M
-2.2x
---
United StatesTIL
Instil Bio Inc
179.7M
-1.4x
---
United StatesATAI
ATAI Life Sciences NV
181.2M
-2.8x
---
United StatesGOSS
Gossamer Bio Inc
200.5M
-2.2x
---
As of 2024-11-06

Company Information

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. It has also produced a potential novel treatment for severe inflammatory diseases, DM300, which is in the early preclinical stage of development. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation in the body, as well as an important role in reducing inflammation and oxidative stress.

Contact Information

Headquarters
301 CARLSON PARKWAY, SUITE 210MINNEAPOLIS, MN, United States 55305
Phone
763-496-5454
Fax
763-710-4456

Executives

Independent Chairman of the Board
Richard Pilnik
President, Chief Executive Officer, Director
Rick Pauls
Chief Financial Officer, Company Secretary
Scott Kellen
Chief Technology Officer
Ambarish Shah
Chief Commercial Officer
Dominic Cundari

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$186.8M
Revenue (TTM)
$0.00
Shares Outstanding
42.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.45
EPS
$-0.52
Book Value
$1.35
P/E Ratio
-8.3x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.